Author

Xiang Gao

Observed institution: Sixth Affiliated Hospital of Sun Yat-sen University

ORCID: 0009-0004-6121-7083

Observed ORCID: 0009-0004-6121-7083

OpenAlex ID: A5006523262

Risankizumab for Ulcerative Colitis

2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

2024 · Marc Ferrante, Marc Ferrante, et al. · The Lancet · 120

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment

2022 · Edward V. Loftus, Jean-Frederic Colombel, et al. · Clinical Gastroenterology and Hepatology · 107

Tu1918 RUMINOCOCCUS GNAVUS MAY MEDIATE PATHOGENESIS OF A DISTINCT METABOLIC IRRITABLE BOWEL SYNDROME PHENOTYPE CHARACTERIZED ALTERED BILE ACID EXCRETIONS AND FEATURES OF METABOLIC SYNDROME

2024 · Andrea S. Shin, Yue J. Xing, et al. · Gastroenterology · 1

967: Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1

2022 · Séverine Vermeire, Jean Frederic Colombel, et al. · Gastroenterology · 1

Histologic and combined histologic–endoscopic outcomes with mirikizumab in Crohn’s disease: VIVID-1 trial results

2026 · Vipul Jairath, Fernando Magro, et al. · Journal of Crohn s and Colitis

Works count: 7

Citation count: 475

H-index: 4

I10-index: 4